Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNTRA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļNatera Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 02, 2015
āļāļĩāļāļĩāđāļMr. Steven Leonard (Steve) Chapman
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ4424
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 02
āļāļĩāđāļāļĒāļđāđ13011 Mccallen Pass
āđāļĄāļ·āļāļAUSTIN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ78753
āđāļāļĢāļĻāļąāļāļāđ16502499090
āđāļ§āđāļāđāļāļāđhttps://www.natera.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNTRA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 02, 2015
āļāļĩāļāļĩāđāļMr. Steven Leonard (Steve) Chapman
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
Mr. Jonathan Sheena
Co-Founder, Director
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
Herman Rosenman, CPA
Independent Director
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Dr. Rowan E. Chapman, Ph.D.
Dr. Rowan E. Chapman, Ph.D.
Independent Director
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
Mr. Jonathan Sheena
Co-Founder, Director
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
Herman Rosenman, CPA
Independent Director
Franklin Genomic Advancements ETF
Alger Weatherbie Enduring Growth ETF
ARK Genomic Revolution ETF
Global X Genomics & Biotechnology ETF
First Trust Nasdaq Lux Digi Health Solutions ETF
Invesco Dorsey Wright Healthcare Momentum ETF
TrueShares Technology, AI & Deep Learning ETF
First Trust NYSE Arca Biotechnology Index Fund
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ6.11%
Alger Weatherbie Enduring Growth ETF
āļŠāļąāļāļŠāđāļ§āļ5.61%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ4.16%
Alger 35 ETF
āļŠāļąāļāļŠāđāļ§āļ4.03%
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ3.94%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
āļŠāļąāļāļŠāđāļ§āļ3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļāļŠāđāļ§āļ3.38%
TrueShares Technology, AI & Deep Learning ETF
āļŠāļąāļāļŠāđāļ§āļ3.21%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.12%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ